scroll
14 DAYS FREE ACCESS
Join Market Matters and get full access
to all our Opinion + Action
ASX.IMU $0.20
20 MINUTE DELAYED
ANALYSIS
OPINION
ACTION
i
PERFORMANCE
i
SHARE PRICE ACTIVITY | |
---|---|
Last (Price) | 0.20 |
Change | 0.02 (8.33) |
Bid / Ask | 0.20 - 0.20 |
Volume | 20,200,371 |
Volume (3mths avg) | 0 |
Turnover | 3,946,789 |
Open | 0.19 |
Day Range | 0.18 - 0.21 |
VWAP | 0.20 |
Prev Close | 0.18 |
Last Trade | 06.10 01/07 (AEST) |
i
KEY INFORMATION | |
---|---|
Sector | Healthcare |
Shares Issued | 4,885,986,365 |
NTA/Share | 0.00 |
Last Dividend | 0.00 |
Dividend Ex Date | |
Dividend Pay Date | 29 MAR 2006 |
i
CURRENT () | |
---|---|
Revenue | |
EBITDA | |
Profit | |
Earnings Per Share (EPS) | 0.00 |
Dividend Per Share (DPS) | 0.00 |
Yield % | 0.00 |
Market Cap | 0.00 |
Price to Earnings Ratio (P/E) | 0 |
i
TARGET PRICE FORECAST
i
ESTIMATES () | |
---|---|
Revenue | 0.00 |
EBITDA | 0.00 |
Profit | 0.00 |
Earnings Per Share (EPS) | 0.00 |
Dividend Per Share (DPS) | 0.00 |
i
BROKER CONSENSUS RECOMMENDATION
BUY
SELL
Target Price
0.00
Lt Growth Rate
0.00
Recommendation ()
0.00
ACTION
IMU
UPDATED
07/06/2022 17:40
MM is neutral IMU – one for a high risk punt ~17c for the brave using stops below 15c
Add To Hit List
IMU
UPDATED
22/03/2022 23:08
Business Summary
Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.Relevant suggested news and content from the site
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.